ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS)
The ESMO-MCBS is a tool developed by the European Society for Medical Oncology to rate how much benefit patients are likely to get from new cancer treatments. It helps distinguish between small, minor improvements and large, meaningful benefits in outcomes like survival or quality of life, based on evidence from clinical trials.
At a glance
Use when
Evaluating the clinical value of new anti-cancer therapies based on trial data; informing reimbursement or guideline decisions; comparing relative benefits of oncology treatments; supporting health technology assessment in cancer care.
Avoid when
Assessing non-oncology interventions; making cost-effectiveness decisions without supplementary economic analysis; relying solely on early-phase or non-randomised study data.
Inputs
Results from high-quality clinical trials, particularly phase III randomised controlled trials, including endpoints such as overall survival, progression-free survival, response rate, duration of response, and patient-reported outcomes.
Outputs
A graded score indicating the magnitude of clinical benefit, categorising anti-cancer therapies into levels of meaningfulness (e.g., high, intermediate, low) based on predefined, validated criteria.
How it works
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, structured scoring system that assesses the magnitude of clinical benefit from anti-cancer therapies using data from phase III randomised controlled trials. It provides a reproducible, standardised framework to rank clinical benefit on a scale, differentiating between trivial and substantial improvements in endpoints such as overall survival, progression-free survival, and patient-reported outcomes. The tool supports transparent, unbiased evaluation of oncology treatments and informs value-based cancer care decisions. Criteria are periodically updated to reflect evolving standards.
- HTA domains
- Clinical Effectiveness, Patient and Social Aspects
- Assumptions
- Clinical trial data are robust, unbiased, and representative of real-world populations; clinically significant endpoints are prioritised over surrogate markers; and improvements in survival or quality of life reflect meaningful patient benefit.
- Strengths
- Provides a standardised, transparent, and reproducible method for evaluating clinical benefit; reduces overstatement of marginal results; supports value-based decision-making; regularly updated to reflect new evidence and standards of care.
- Limitations
- Primarily focused on oncology; may not fully capture long-term or rare benefits and harms; limited ability to incorporate real-world evidence; does not directly quantify cost-effectiveness.
- Also known as
- ESMO-MCBS, ESMO Magnitude of Clinical Benefit Scale
Questions this answers
- › How clinically meaningful is the benefit of a new cancer treatment?
- › Does the treatment provide a substantial improvement in survival or quality of life?
- › Is the observed benefit large enough to justify changes in clinical practice?
- › How does this therapy compare to others in terms of patient-relevant outcomes?
- › Can the treatment's benefit be considered 'breakthrough' or only marginal?
- › What is the evidence-based ranking of clinical benefit for this oncology intervention?
References & sources
Similar by meaning
- Core outcome set for metastatic breast cancer (MBC)
- IQWiG threshold method for extent of added benefit (minor/considerable/major)
- Effect size benchmark values for quantifying benefit/risk of medicinal products
- SMR / ASMR (Service Medical Rendu / Amelioration du Service Medical Rendu)
- SMC Patient and Clinician Engagement (PACE) process
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.